Clinical trial NCT05200728: The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers
Official title: A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, and PK Characteristics of SIM1910-09 After Single/Multiple Dosing in Healthy Chinese Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Ischemic Stroke
Cerebral Edema
Keywords: brain edema
Acute ischemic stroke
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-01-21
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the tolerability, safety, and pharmacokinetic characteristics of SIM1910-09 for injection after single/multiple dosing in healthy Chinese adult volunteers.

Detailed description: This is a double-blind, randomized, placebo-controlled, sequential-group study with intravenously (IV) administered SIM1910-09 in healthy human subjects to assess the safety, tolerability and pharmacokinetic parameters, which include of single ascending dose part and multiple ascending doses part. The primary objectives of this study are to assess the safety and tolerability of SIM1910-09 in healthy subjects. Secondary objectives are to determine the pharmacokinetics of SIM1910-09 and SCR-6401 (primary metabolite) after administration of SIM1910-09. Exploratory objectives are to learn the inhibitory effect of SIM1910-09 and SCR-6401 on inflammation cytokine in ex vivo blood.

Eligibility criteria: Inclusion Criteria:

1. Chinese male or female healthy volunteers;
2. The subject fully understood the purpose, procedure, requirements, study period and potential risks of the study, and have signed the informed consent form (ICF);
3. Age 18-50 years (including the boundary value) at the date of signing ICF ;
4. The weight of Male subjects is no less than 50 kg, the one of female subjects no less than 45 kg, and body mass index (BMI) should be in the range of 19-28 kg/m2 (including the boundary value)

Exclusion Criteria:

1. Those who participated in blood donation with blood donation volume ≥400 mL within 3 months prior to the first drug administration, or those who received blood transfusion;
2. Those who have a history of clinically significant drug allergy or allergic reaction, as determined by the investigator, and is known to be allergic to the study drug or any of the ingredients in the study drug;
3. Those who have a history of drug addiction and/or alcohol abuse, or positive result in drugs and alcohol screening test, or have had a history of drug abuse in the past five years or have used drugs in the three months before screening; or positive result in urine drug screening test during screening period;
4. Alcohol and tobacco users (drinking more than 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine; Smokers who smoke 5 or above cigarettes a day) and cannot abstain from smoking or alcohol during the trial period; Or positive result in urine cotinine test ;
5. Fridericia method corrected QT interval (QTcF) \> 450 msec in males or \> 470 msec in female in 12-lead electrocardiogram;
6. Those who have a definite disease history of important organs, such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic system and skeletal musculoskeletal system, which are not suitable for attending this study according to the investigator' judgement;
7. Those who have undergone any surgery operation within 6 months prior to the first dose;
8. Those who have taken hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) within 6 months before the first dose;
9. Have taken any investigational drug within 3 months prior to the first dose;
10. Have taken any prescription medicine or over-the-counter drug, any vitamin product, health care product or herbal medicine within 2 weeks prior to initial administration;
11. Abnormalities in comprehensive physical examination (vital signs, physical examination, neurological examination), routine laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead ECG, chest X-ray, cognitive function and other examinations, which are judged as clinically significant by investigators;
12. Female subjects who are pregnant or in lactation, or who are unable to abstain from sex or unable to use effective non-pharmacological contraception during the study period and during 3 months after final dose, or who have had unprotected sexual intercourse in the 2 weeks prior to the first dose;
13. The positive result in the Infectious disease screening (including HBSAG, HCV-AB, HIV-AB, syphilis antibody) ;
14. Intake of grapefruit or grapefruits-containing products, foods or beverages containing caffeine, xanthine or alcohol within 48 hours prior to administration of the study drug; Or other factors of affecting drug absorption, distribution, metabolism, excretion.;
15. Patients with a history of needle sickness or blood sickness, or resistance for blood collection or intolerance to venipuncture blood collection;
16. Subjects with other inappropriate factors for attending this study judged by investigators.

Primary outcomes:
measure: the adverse events after single/multiple ascending dosing in healthy Chinese adult subjects
timeFrame: 7 days after final dose
measure: the clinically significant change from baseline of physical examinations after single/multiple ascending dosing in healthy Chinese adult subjects
timeFrame: 7 days after final dose
measure: the clinically significant change from baseline of the vital signs after single/multiple ascending dosing in healthy Chinese adult subjects
timeFrame: 7 days after final dose
measure: the clinically significant change from baseline of laboratory tests after single/multiple ascending dosing in healthy Chinese adult subjects
timeFrame: 7 days after final dose
measure: the clinically significant change from baseline of 12-lead electrocardiograms after single/multiple ascending dosing in healthy Chinese adult subjects
timeFrame: 7 days after final dose
Secondary outcomes:
measure: PK parameters: Peak Plasma Concentration (Cmax)
timeFrame: Within 1-2 weeks of final blood sample collection
measure: PK parameters: Area under the plasma concentration versus time curve (AUC)
timeFrame: Within 1-2 weeks of final blood sample collection
measure: PK parameters: Clearance (CL)
timeFrame: Within 1-2 weeks of final blood sample collection
measure: PK parameters: Half-life (t1/2)
timeFrame: Within 1-2 weeks of final blood sample collection
measure: PK parameters: Volume of distribution (V)
timeFrame: Within 1-2 weeks of final blood sample collection
Other outcomes:
measure: Exploratory outcome: The cytokines Concentrations of interleukin 1β (IL-1β)
timeFrame: Within one week of final blood sample collection
measure: Exploratory outcome: The cytokines Concentrations of interleukin 6 (IL-6)
timeFrame: Within one week of final blood sample collection
measure: Exploratory outcome: The cytokines Concentrations of tumor necrosis factor α (TNF-α)
timeFrame: Within one week of final blood sample collection
measure: Exploratory outcome: The cytokines Concentrations of interferon γ (IFN-γ)
timeFrame: Within one week of final blood sample collection
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital, Capital Medical University
state: Beijing
Study officials:
affiliation: Beijing Tiantan Hospital
name: Yongjun Wang
role: PRINCIPAL_INVESTIGATOR
References: